Private Health Insurance – The News Desk

Cigna Calls Off Humana Pursuit, Plans Big Stock Buyback

10Dec

By adminNo Comments

Money

Cigna Calls Off Humana Pursuit, Plans Big Stock Buyback

Updated Dec. 10, 2023 12:38 pm ETCigna abandoned its pursuit of a tie-up with Humana that would have created a roughly $140 billion giant in the health-insurance industry.The companies couldn’t come to agreement on price and other financial terms, according to people familiar with the matter. In the near term, Cigna is turning its focus toward smaller, so-called bolt-on, acquisitions.Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8

10Dec

By adminNo Comments

World

Cigna Calls Off Humana Pursuit, Plans Big Stock Buyback

Updated Dec. 10, 2023 12:38 pm ETCigna abandoned its pursuit of a tie-up with Humana that would have created a roughly $140 billion giant in the health-insurance industry.The companies couldn’t come to agreement on price and other financial terms, according to people familiar with the matter. In the near term, Cigna is turning its focus toward smaller, so-called bolt-on, acquisitions.Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8

6Dec

By adminNo Comments

Money

The Medicare Gold Rush Is Slowing Down

The popularity of private Medicare plans has been a huge driver of profits for insurance companies in recent years. There are signs the gold rush isn’t quite what it once was.Investors have been worried all year as the Biden administration phases in a new system that insurers say will reduce federal payments to Medicare Advantage plans. Developments last week at the top two insurers in the Medicare business, UnitedHealth Group and Humana, raised more questions. Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8

Cigna, Humana in Talks for Blockbuster Insurance Merger in Stock-and-Cash Deal

30Nov

By adminNo Comments

World

Cigna, Humana in Talks for Blockbuster Insurance Merger in Stock-and-Cash Deal

Updated Nov. 29, 2023 4:28 pm ETCigna and Humana are in talks for a combination that would create a new powerhouse in the health-insurance industry. The companies are discussing a stock-and-cash deal that could be finalized by the end of the year, assuming the talks don’t fall apart, according to people familiar with the matter. Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8

Cigna, Humana in Talks for Blockbuster Merger

29Nov

By adminNo Comments

Money

Cigna, Humana in Talks for Blockbuster Merger

Updated Nov. 29, 2023 12:24 pm ETCigna and Humana are in talks for a combination that would create a new powerhouse in the health-insurance industry. The companies are discussing a stock-and-cash deal that could be finalized by the end of the year, assuming the talks don’t fall apart, according to people familiar with the matter. Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8

26Oct

By adminNo Comments

World

Health Care Roundup: Market Talk

The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET.2128 GMT – Molina Healthcare keeps its outlook for the year unchanged after posting profit and revenue growth in 3Q. The company’s quarterly results were largely consistent with management expectations, “in addition to considerations of seasonality and conservatism,” Molina Healthcare says. The company’s revenue beat analysts expectations, but earnings per share came below forecasts in the period.Shares rise 0.5% after hours. (sabela.ojea@wsj.com; @sabelaojeaguix)Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8

Ozempic Boom Is an Opportunity for Health Insurers

20Oct

By adminNo Comments

Money

Ozempic Boom Is an Opportunity for Health Insurers

You would think a new class of high-price weight loss drugs taken by millions of Americans would be a problem for health insurers. After all, they ultimately foot the bill. But it is more complicated than that: Some insurance giants actually stand to profit from the Ozempic craze.The industry has been calling out the costs of GLP-1 drugs, which are used for both diabetes and obesity. But federally supported Medicare and Medicaid still don’t cover the drugs for obesity, and much of the commercial market is self-insured. In other words, even though your insurance card says “Aetna” or “UnitedHealthcare,” those companies in some cases only act as administrators. That means employers are the ones bearing the risk of runaway costs.Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserve...